Se încarcă compania
Just reported
Q3 2026 results
From Moderna's results release of 6 noiembrie 2026; its quarterly report has since been filed.
Revenue
Actual
1,31B USD
+29 % y/y
Guided
—
No guide given
EPS, GAAP
Actual
0,38 USD
Guided
—
No guide given
Operating income, GAAP
Actual
130M USD
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Keep exploring
The themes Moderna is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B USDA+
EXELExelixis, Inc.16,8B USDA+
JAZZJazz Pharmaceuticals plc15,5B USDA
TECHBIO-Techne Corp11,4B USDA+
HALOHalozyme Therapeutics, Inc.11,4B USDA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct. 2026CBGraded C, now B
MCKMckesson Corporation4 nov. 2026BAGraded B, now A
CVSCVS Health Corp4 nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov. 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 oct. 2026CAGraded C, now A
Cum face bani
- COVID-19 vaccine sales, including Spikevax and mNEXSPIKE93 %
- Payments for manufacturing capacity4 %
- Government and other grants1 %
- Collaboration revenue1 %
- Licensing and royalties1 %
- RSV vaccine sales, including mRESVIA0 %
Ponderile din venituri sunt estimări pentru year ended 2025-12-31, nu cifre dintr-un raport depus.
Concurează cu
Ce vinde6
Spikevax
A COVID-19 vaccine updated to target circulating virus variants.
mNEXSPIKE
A COVID-19 vaccine that uses a lower mRNA dose than Spikevax and focuses the immune response on key parts of the virus.
mRESVIA
An RSV vaccine for older adults and certain adults at increased risk of severe RSV illness.
Afișează încă 3
mFLUSIVA
An influenza vaccine approved in the United States and Canada for adults aged 50 and older; commercial sales began in September 2026.
mCOMBRIAX
A vaccine combining protection against influenza and COVID-19, authorized in Europe and Canada for adults aged 50 and older; it had not been commercialized by September 30, 2026.
Intismeran autogene (mRNA-4157)
An investigational personalized cancer treatment designed around mutations in an individual patient's tumor; it is being developed with Merck alongside pembrolizumab.
Cine cumpără4
- Wholesalers and distributors, which are the main route for sales in the United States.
- Retail pharmacies, health care providers and government entities, which also buy vaccines in the United States.
- Governments and international organizations that purchase vaccines.
- Governments in the United Kingdom, Canada and Australia, which have multi-year commitments to purchase mRNA products.
Pe ce se sprijină și ce l-ar putea dărâma
De ce depinde activitatea
- 1COVID-19 vaccine sales made up 93.1% of revenue in 2025, tying revenue closely to demand for those vaccines.
- 2Vaccine sales are seasonal and depend on public health recommendations, changes in circulating viruses and whether people choose to get vaccinated.
- 3Some materials and manufacturing processes rely on single-source suppliers, and the company also uses outside manufacturers and suppliers.
- 4Intismeran autogene is being developed with Merck, with development costs and potential profits or losses generally shared equally.
- 5Vaccine products can require cold storage and careful shipping.
Ce ar putea merge prost
- 1Demand for seasonal vaccines can change with public health recommendations, virus circulation, customer orders and willingness to vaccinate; these changes can affect sales.
- 2Clinical trials and regulatory reviews may delay or prevent approval of new vaccines and treatments; the influenza vaccine mRNA-1010 had faced a regulatory filing setback before its amended application was accepted for review.
- 3Manufacturing or supply problems, including supplier interruptions, product-release issues or failures to maintain required shipping and storage conditions, could delay or limit product supply.
Situațiile financiare complete →
Despre Moderna, Inc.
Moderna makes vaccines using messenger RNA (mRNA), which gives cells instructions to make a protein that can help prevent or treat disease. It also develops mRNA-based treatments, including a personalized cancer treatment being developed with Merck and treatments for rare inherited diseases. As of September 30, 2026, it had five approved products, though its flu-plus-COVID vaccine had not yet been commercialized.
- Sediu
- Cambridge, Massachusetts
- Înființată în
- 2010
- Listată la
- Nasdaq
- Sfârșitul exercițiului financiar
- December 31
Construit din raportările proprii ale Moderna, Inc. la Comisia pentru Valori Mobiliare și Burse a SUA (SEC). Cifrele sunt cele raportate, iar istoricul pe acțiune este recalculat la baza de acțiuni de azi. Aceasta descrie o afacere — nu este consultanță de investiții și nu este o recomandare de cumpărare sau vânzare.